FMP

FMP

Enter

INBX - Inhibrx Biosciences,...

photo-url-https://images.financialmodelingprep.com/symbol/INBX.png

Inhibrx Biosciences, Inc.

INBX

NASDAQ

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

14.1 USD

-0.05 (-0.355%)

Operating Data

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

9.09M

12.81M

7.13M

2.18M

1.8M

1.39M

1.08M

835.43k

646.82k

500.8k

Revenue %

-

40.86

-44.37

-69.43

-17.36

-22.58

-22.58

-22.58

-22.58

Ebitda

-42.6M

-67.44M

-76.56M

-125.82M

-206.69M

-1.39M

-1.08M

-835.43k

-646.82k

-500.8k

Ebitda %

-468.54

-526.57

-1.07k

-5.78k

-11.48k

-100

-100

-100

-100

Ebit

-45.12M

-69.84M

-79.25M

-127.04M

-207.88M

-1.39M

-1.08M

-835.43k

-646.82k

-500.8k

Ebit %

-496.23

-545.25

-1.11k

-5.83k

-11.55k

-100

-100

-100

-100

Depreciation

2.52M

2.39M

2.69M

1.23M

1.19M

575.61k

445.66k

345.05k

267.15k

206.84k

Depreciation %

27.69

18.68

37.73

56.24

66.17

41.3

41.3

41.3

41.3

EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep